CDX 1307
Alternative Names: CDX-1307; MDX-1307Latest Information Update: 14 Sep 2023
At a glance
- Originator Medarex
- Developer Celldex Therapeutics Inc
- Class Immunotherapies; Monoclonal antibodies; Vaccines
- Mechanism of Action Antibody-dependent cell cytotoxicity; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Discontinued Bladder cancer; Breast cancer; Colorectal cancer; Ovarian cancer; Pancreatic cancer
Most Recent Events
- 17 Feb 2012 Discontinued - Phase-I for Breast cancer in USA (Intradermal)
- 17 Feb 2012 Discontinued - Phase-I for Breast cancer in USA (IV)
- 17 Feb 2012 Discontinued - Phase-I for Colorectal cancer in USA (Intradermal)